Misoprostol prophylaxis for high-dose chemotherapy-induced mucositis: a randomized double-blind study

Area of Science:

• Oncology
• Hematology
• Pharmacology

Background:

• High-dose chemotherapy followed by peripheral stem cell transplantation (HDC-PSCT) is a standard treatment for various neoplasms.
• Mucositis, a common and debilitating side effect of HDC-PSCT, significantly impacts patient quality of life and treatment outcomes.
• Oral misoprostol has been investigated as a potential agent for mucositis prophylaxis.

Purpose of the Study:

• To evaluate the efficacy of oral misoprostol in preventing chemotherapy-induced mucositis during HDC-PSCT.
• To assess the impact of misoprostol on other chemotherapy-related complications, including myelosuppression and infections.

Main Methods:

• A double-blind, randomized clinical trial involving 15 patients with lymphoid or solid neoplasms undergoing HDC-PSCT.
• Patients received the ICE (ifosfamide, carboplatin, etoposide) regimen.
• Intervention group received oral misoprostol, while the control group received a placebo, starting from day -4 to day 16 relative to transplantation.

Main Results:

• A significantly higher incidence and severity of mucositis were observed in patients treated with oral misoprostol compared to placebo.
• No significant differences were found between the misoprostol and placebo groups regarding myelosuppression, infections, or other chemotherapy complications.
• The study did not demonstrate any benefit of oral misoprostol for mucositis prophylaxis in this patient population.

Conclusions:

• Oral misoprostol, administered as per this study protocol, is not effective for preventing high-dose chemotherapy-induced mucositis.
• The findings do not support the use of oral misoprostol for mucositis prophylaxis in patients undergoing HDC-PSCT.
• Further research may be needed to explore alternative prophylactic strategies for mucositis.